120 PRESIDENTIAL WAY,, WOBURN, MA
Annual Meeting of Stockholders - Directors Elected: Beth J. Hoffman, Kevin D....
Reports First Quarter 2026 Financial Results and Provides a Business Update
Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for Moderate to Severe Acne Vulgaris
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Patent 11,697,028 To Be Unpatentable
Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Amended Annual Report
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-1
Amended Registration Statement for Securities
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Definitive Revised Proxy Statement